2003, Pharmaceutical research and Side effects

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

SEPTEMBER 22, 2023

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience.

Food and Drug Administration

Food and Drug Administration Safety Patients Leads

Beating the Big C

Pharmaceutical Technology

JULY 23, 2008

” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.” However, there’s still plenty of cancers where treatment can only prolong life by two to three months and then only with side effects that bring up serious quality of life issues. We’re on the right path.”

Side effects

Side effects Marketing Pharmaceutical Sales

Pharma Rep Focus

Paving the way for anti-Abeta active immunotherapy

Beating the Big C

Webinars

Stay Connected